Dynamic mathematical modeling of IL13-induced signaling in Hodgkin and primary mediastinal B-cell lymphoma allows prediction of therapeutic targets.

Division of Systems Biology of Signal Transduction, DKFZ-ZMBH Alliance and Molecular Genetics, German Cancer Research Center, Heidelberg, Germany.
Cancer Research (Impact Factor: 9.28). 02/2011; 71(3):693-704. DOI: 10.1158/0008-5472.CAN-10-2987
Source: PubMed

ABSTRACT Primary mediastinal B-cell lymphoma (PMBL) and classical Hodgkin lymphoma (cHL) share a frequent constitutive activation of JAK (Janus kinase)/STAT signaling pathway. Because of complex, nonlinear relations within the pathway, key dynamic properties remained to be identified to predict possible strategies for intervention. We report the development of dynamic pathway models based on quantitative data collected on signaling components of JAK/STAT pathway in two lymphoma-derived cell lines, MedB-1 and L1236, representative of PMBL and cHL, respectively. We show that the amounts of STAT5 and STAT6 are higher whereas those of SHP1 are lower in the two lymphoma cell lines than in normal B cells. Distinctively, L1236 cells harbor more JAK2 and less SHP1 molecules per cell than MedB-1 or control cells. In both lymphoma cell lines, we observe interleukin-13 (IL13)-induced activation of IL4 receptor α, JAK2, and STAT5, but not of STAT6. Genome-wide, 11 early and 16 sustained genes are upregulated by IL13 in both lymphoma cell lines. Specifically, the known STAT-inducible negative regulators CISH and SOCS3 are upregulated within 2 hours in MedB-1 but not in L1236 cells. On the basis of this detailed quantitative information, we established two mathematical models, MedB-1 and L1236 model, able to describe the respective experimental data. Most of the model parameters are identifiable and therefore the models are predictive. Sensitivity analysis of the model identifies six possible therapeutic targets able to reduce gene expression levels in L1236 cells and three in MedB-1. We experimentally confirm reduction in target gene expression in response to inhibition of STAT5 phosphorylation, thereby validating one of the predicted targets.

1 Bookmark
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Since the publication of Leonor Michaelis and Maude Menten's paper on the reaction kinetics of the enzyme invertase in 1913, molecular biology has evolved tremendously. New measurement techniques allow for in vivo characterization of the whole genome, proteome or transcriptome of cells whereas the classical enzyme essay only allows to determine the two Michaelis-Menten parameters and Km. Nevertheless, Michaelis-Menten kinetics is still highly used not only in the in vitro context of enzyme characterization but also as a rate law for enzymatic reactions in larger biochemical reaction networks. In this review, we want to give an overview of the historical development of kinetic rate laws originating from Michaelis-Menten kinetics over the past 100 years. Furthermore, we briefly summarize the experimental techniques used for the characterization of enzymes and make an excursus on web resources that systematically store kinetic parameters and related information. Finally, we want to present the novel opportunities that arise from using these data in dynamic mathematical modeling. In this framework, traditional in vitro approaches can be combined with modern genome scale measurements to foster thorough understanding of the underlying complex mechanisms. This article is protected by copyright. All rights reserved.
    FEBS Journal 11/2013; · 3.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Diffuse and unstoppable infiltration of brain and spinal cord tissue by neoplastic glial cells is the single most important therapeutic problem posed by the common glioma group of tumors: astrocytoma, oligoastrocytoma, oligodendroglioma, their malignant variants and glioblastoma. These neoplasms account for more than two thirds of all malignant central nervous system tumors. However, most glioma research focuses on an examination of the tumor cells rather than on host-specific, tumor micro-environmental cells and factors. This can explain why existing diffuse glioma therapies fail and why these tumors have remained incurable. Thus, there is a great need for innovation. We describe a novel strategy for the development of a more effective treatment of diffuse glioma. Our approach centers on gaining control over the behavior of the microglia, the defense cells of the CNS, which are manipulated by malignant glioma and support its growth. Armoring microglia against the influences from glioma is one of our research goals. We further discuss how microglia precursors may be genetically enhanced to track down infiltrating glioma cells.
    CNS & neurological disorders drug targets 09/2013; · 3.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Activation of the antigen receptors on the surface of B cells in response to their cognate ligands is tightly controlled by feedback mechanisms. Apart from ligand induced signaling, B cell receptors (BCRs) emanate ligand independent tonic signaling crucial for B cell survival and development. In the absence of a ligand, BCR tonic signaling is controlled by the basal activity of the Src family protein tyrosine kinase Lyn and the protein tyrosine phosphatase SHP. The binding of an antigen to the BCR causes receptor clustering or aggregation which is one of the earliest events in B cell activation. Lyn binds to aggregated receptors and phosphorylates them. In turn phosphorylation enhances the stability of receptor clusters against dissociation into monomers as well as the binding of Lyn to the receptor clusters, thereby producing positive feedback loops that enhance receptor clustering and activation. Apart from Lyn mediated positive feedback loops, SHP and BCR aggregates mutually inhibit each other to form a double negative feedback loop. Here, we present a simple computational model of BCR proximal signaling that incorporates these multiple feedback loops between the three molecules BCR, Lyn and SHP and their complexes. The model predicts bistable behaviour in the system that explains both the tonic signaling and ligand mediated receptor activation and a range of other biological phenomena in a unified manner. We find the bistability to be highly tunable by changes in the protein levels while remaining sufficiently robust to changes in the rate constants. The nested architecture of multiple feedback loops enhances the robustness of the bistability. Our model explains the recent experimental observation of the lack of response of germinal center B cells to ligand stimulation in terms of the tunability of the bistable switch by modification of SHP levels.
    Molecular BioSystems 07/2013; · 3.35 Impact Factor


Available from
Oct 22, 2014